Category: Lyon
RICHMOND, Va. (Nov. 20, 2009) -- Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine researchers have identified a gene that may play a pivotal role in two processes that are essential for tumor development, growth and progression to metastasis.
Montreal, November 17, 2009 -- More than six percent of expectant mothers in Quebec consume prescription drugs that are known to be harmful to their fetuses, according to a Université de Montréal investigation published in the British Journal of Obstetrics and Gynaecology.
Ridgefield, CT, November 16, 2009 - Data from pivotal Phase III clinical trials demonstrate that flibanserin 100mg increased the number of satisfying sexual events (SSE) and sexual desire (the co-primary endpoints) while decreasing the distress associated with Hypoactive Sexual Desire Disorder (HSDD).
In an encouraging development, an investigational vaccine regimen has been shown to be well-tolerated and to have a modest effect in preventing HIV infection in a clinical trial involving more than 16,000 adult participants in Thailand. Following a final analysis of the trial data, the Surgeon General of the U.S.
COLD SPRING HARBOR, N.Y. (Wed., Aug. 5, 2009) -- Vectors derived from retroviruses are useful tools for long-term gene transfer because they allow stable integration of transgenes and propagation into daughter cells. Lentiviral vectors are preferred because they can transduce non-proliferating cellular targets. These vectors can be engineered to target specific tissues.
This week I am in Lyon, France, for the 3rd Experimental Pragmatics meeting. I had plans to live-blog CUNY and SRCD, neither of which quite happened, but I'm giving it a go for Day 2 of Xprag, and we'll see how it goes.
Axentis Pharma AG is to present its recent successes in developing and financing a new therapeutic formulation for treating chronic lung disease at the 2nd Annual European Life Science CEO Forum in Zurich, Switzerland.
